Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 15.4% in the 1st quarter, Holdings Channel.com reports. The fund owned 6,118 shares of the medical research company’s stock after acquiring an additional 817 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Charles River Laboratories International were worth $952,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Metis Global Partners LLC increased its holdings in Charles River Laboratories International by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock worth $318,000 after acquiring an additional 72 shares in the last quarter. Two Sigma Securities LLC grew its holdings in shares of Charles River Laboratories International by 4.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company’s stock worth $366,000 after buying an additional 81 shares in the last quarter. Wahed Invest LLC grew its holdings in shares of Charles River Laboratories International by 6.5% during the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company’s stock worth $244,000 after buying an additional 81 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Charles River Laboratories International by 16.3% during the fourth quarter. Jones Financial Companies Lllp now owns 641 shares of the medical research company’s stock worth $118,000 after buying an additional 90 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its holdings in shares of Charles River Laboratories International by 0.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company’s stock worth $2,897,000 after buying an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.2%

Shares of CRL stock opened at $157.12 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The firm has a market cap of $7.72 billion, a PE ratio of -241.72, a price-to-earnings-growth ratio of 5.32 and a beta of 1.49. The company has a 50-day moving average of $140.70 and a two-hundred day moving average of $152.71. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. Charles River Laboratories International’s revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.27 earnings per share. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president owned 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CRL shares. Redburn Atlantic raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Barclays upped their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an “equal weight” rating in a report on Thursday, May 8th. Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Wednesday, May 14th. Robert W. Baird raised their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, May 8th. Finally, TD Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).